Events

Wired Health w/ Joanna Shields

Join BenevolentAI’s CEO Joanna Shields at Wired Health where she will be speaking about forging new frontiers in drug discovery by uniting human and artificial intelligence.

While the past year has reinforced the fragility of human health, it has also demonstrated the value of leveraging AI to solve some of healthcare's greatest challenges. The speech will draw on BenevolentAI's pioneering work and powerful collaborations with leading pharma companies to further illustrate where AI has had a proven impact, both during the pandemic and in drug discovery more generally. Joanna will reflect on lessons learned from her leadership experience in big tech and government to lay out her vision for the future of scientific discovery: where human and artificial intelligence are united to solve complex pharmaceutical puzzles, unlock the value of vast data sets, and deliver new life-changing treatments to patients in need.


Register here →


Joanna Shields

Chief Executive Officer

Joanna is a tech industry veteran with over 25 years experience building and scaling global companies including Facebook, Bebo, Aol, Google, Real Networks and Efi. Prior to joining Benevolent AI, she served in UK Government as Under Secretary of State and Minister for Internet Safety & Security, Digital Economy Adviser and Chair and CEO of TechCityUK. Joanna is passionate about creating responsible technology that benefits humanity. She is a leading advocate for children's rights and safety online and founder of the WeProtect Global Alliance, and a Life Peer of the House of Lords.

More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021